Breaking News, Trials & Filings

Merck’s Keytruda Approved in EU for Treatment of Recurrent Ovarian Cancers

It will be the first and only PD-1 inhibitor-based option available for EU patients with platinum-resistant ovarian cancer.

Author Image

By: Patrick Lavery

Content Marketing Editor

Merck, known as MSD outside the U.S. and Canada, has gained approval for Keytruda (pembrolizumab) in the European Union (EU). The approval is granted for use in combination with paclitaxel, and with or without bevacizumab. This use of Keytruda is approved for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Their tumors must express PD-L1 with a Combined Positive Score (CPS) of greater than or equal to 1. Additionally, these patients ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters